Date of publication: November 29, 2021 Decision of the Secretary of Health: Approved (03 December 2021) Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the continue reading : COVID-19 Vaccine Sinopharm for the Prevention of COVID-19
Whole Virion, Inactivated Coronavirus [Covaxin] for the Prevention of COVID-19
Date of publication: November 29, 2021 Decision of the Secretary of Health: Approved (03 December 2021) Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the continue reading : Whole Virion, Inactivated Coronavirus [Covaxin] for the Prevention of COVID-19
Booster and Additional Dose for the Prevention of COVID-19
Date of publication: November 03, 2021 Decision of the Secretary of Health: Approved Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of continue reading : Booster and Additional Dose for the Prevention of COVID-19
Rapid Antigen Test Kits for the Diagnosis of COVID-19 (September 2021 Updates)
Date of publication: September 27, 2021 Objectives: Evidence Summary: Use of Rapid Antigen Test Kits for the Diagnosis of COVID-19 HTAC Recommendation Review:
Tenofovir/Lamivudine/Dolutegravir (TLD) for Treatment-Naive and Treatment-Experienced Adolescents and Adults Living with HIV
Date of publication: August 24, 2021 Approved by the Secretary of Health: September 01, 2021 Evidence Summary: Tenofovir/Lamivudine/Dolutegravir for treatment-naive and treatment-experienced adolescents and adults living with HIV Advisory on non-inclusion in PNF: https://bit.ly/PR_TLD HTAC Recommendation Review: